Molecular Therapy Oncology
Targeting the tumor, harboring the host: IL-7 receptor-targeted CARs to treat T-ALL
By Valeriya V. Kuznetsova, Rishi K. Kothuru, Prasad S. Adusumilli and 1 others.
Abstract
Chimeric antigen receptor (CAR) T cell therapy has fundamentally transformed clinical outcomes in B cell malignancies; however, the success story of CAR T cells has not yet extended to T cell acute lymphoblastic leukemia (T-ALL). A primary issue lies in the fundamental biology of the disease; most target antigens are shared between malignant T-ALL blasts and healthy T lymphocytes, including the CAR T cell product itself.
Keywords
- CAR-T cell therapy research
- Chimeric antigen receptor
- Antigen
- CAR T-cell therapy
- Cell
- T cell
- Leukemia
- Immunotherapy
- Lymphoblastic Leukemia
- Open access
Source
Published in Molecular Therapy Oncology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.